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Abstract Coenzyme Q10 (CoQ10) acts by scavenging
reactive oxygen species for protecting neuronal cells
against oxidative stress in neurodegenerative diseases. We
tested whether a diet supplemented with CoQ10 ameliorates
oxidative stress and mitochondrial alteration, as well as
promotes retinal ganglion cell (RGC) survival in ischemic
retina induced by intraocular pressure elevation. A CoQ10
significantly promoted RGC survival at 2 weeks after
ischemia. Superoxide dismutase 2 (SOD2) and heme oxy-
genase-1 (HO-1) expression were significantly increased at
12 h after ischemic injury. In contrast, the CoQ10 signifi-
cantly prevented the upregulation of SOD2 and HO-1
protein expression in ischemic retina. In addition, the
CoQ10 significantly blocked activation of astroglial and
microglial cells in ischemic retina. Interestingly, the CoQ10
blocked apoptosis by decreasing caspase-3 protein
expression in ischemic retina. Bax and phosphorylated Bad
(pBad) protein expression were significantly increased in
ischemic retina at 12 h. Interestingly, while CoQ10 signif-
icantly decreased Bax protein expression in ischemic ret-
ina, CoQ10 showed greater increase of pBad protein
expression. Of interest, ischemic injury significantly
increased mitochondrial transcription factor A (Tfam)
protein expression in the retina at 12 h, however, CoQ10
significantly preserved Tfam protein expression in ische-
mic retina. Interestingly, there were no differences in
mitochondrial DNA content among control- or CoQ10-
treated groups. Our findings demonstrate that CoQ10 pro-
tects RGCs against oxidative stress by modulating the Bax/
Bad-mediated mitochondrial apoptotic pathway as well as
prevents mitochondrial alteration by preserving Tfam
protein expression in ischemic retina. Our results suggest
that CoQ10 may provide neuroprotection against oxidative
stress-mediated mitochondrial alterations in ischemic reti-
nal injury.
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Introduction
Elevated intraocular pressure (IOP) is an important risk
factor for retinal ganglion cell (RGC) death and optic nerve
degeneration in retinal ischemia and glaucoma [1]. Grow-
ing evidence indicates that ischemic injury by acute IOP
elevation alters mitochondrial dynamics-related proteins
and induces mitochondrial dysfunction-mediated apoptotic
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cell death in the retina of rodent models [2, 3]. Importantly,
our previous studies demonstrated that IOP elevation trig-
gered release of mitochondrial fusion protein optic atrophy
1 and increase of mitochondrial fission GTPase dynamin
related protein-1, as well as induced apoptotic cell death by
modulating Bax/phosphorylated Bad (pBad) protein
expression in ischemic retina [2, 3]. Collectively, these
findings suggest that ischemic injury induced by acute IOP
elevation is associated with mitochondrial dysfunction-
mediated apoptotic pathway in the retina.
Oxidative stress has been implicated as an important
pathophysiological mechanism for mitochondrial dysfunc-
tion-mediated retinal neurodegeneration including ische-
mic injury [4–7]. Superoxide dismutases (SODs), cytosolic
SOD1 and mitochondrial SOD2, are expressed in the
ganglion cell layer (GCL) and inner plexiform layer in
rodent retina [8]. A recent study suggests that SOD2 has a
protective role against oxidative stress-mediated neuronal
cell death [9]. Of interest, we found that acute IOP eleva-
tion significantly increased SOD2 protein expression in the
early neurodegeneration of ischemic rat retina [5]. In
addition, increasing evidence indicates that oxidative stress
is associated with mitochondrial DNA (mtDNA) alteration-
related mitochondrial dysfunction in retinal neurodegen-
eration [5, 7, 10, 11]. However, it remains unknown whe-
ther oxidative stress induced by acute IOP elevation causes
mtDNA alteration in ischemic retinal injury.
Mitochondrial transcription factor A (Tfam, also as
known as mtTFA), a nucleus encoded DNA-binding pro-
tein in mitochondria, has an important role in mitochon-
drial gene expression and mtDNA maintenance, and
therefore is essential for oxidative phosphorylation (OX-
PHOS)-mediated adenosine triphosphate (ATP) synthesis
[12–15]. Mice lacking Tfam have impaired mtDNA tran-
scription and loss of mtDNA leads to bioenergetics dys-
function and embryonic lethality [12]. In contrast,
overexpression of Tfam mediates delayed neuronal death
following transient forebrain ischemia in mice [16–18] as
well as neonatal hypoxic-ischemic brain injury rapidly
increased Tfam and OXPHOS complex IV protein
expression in a rat model [19]. This suggests that these
responses may support endogenous repair mechanisms for
mtDNA damage following hypoxic-ischemic brain injury
[19]. Of note, acute IOP elevation significantly increased
Tfam and OXPHOS complex protein expression in the
early neurodegeneration of ischemic rat retina [5], collec-
tively suggesting that these responses may reflect endoge-
nous repair mechanisms for elevated IOP-induced
mitochondrial alteration in ischemic injury.
Coenzyme Q10 (CoQ10), an essential cofactor of the
electron transport chain, acts by maintaining the mito-
chondrial membrane potential, supporting ATP synthesis
and inhibiting reactive oxygen species (ROS) generation
for protecting neuronal cells against oxidative stress in
neurodegenerative diseases [20–22]. Previous studies have
demonstrated that CoQ10 protected retinal neurons against
hydrogen peroxide-induced oxidative stress in vitro [23] as
well as prevented retinal damage caused by acute high
IOP-induced transient ischemic injury [24, 25].
In the current study, we tested whether a diet supple-
mented with CoQ10 ameliorates oxidative stress-mediated
apoptotic cell death in RGC degeneration by preventing
mitochondrial alteration in ischemic mouse retina.
Materials and methods
Animals
Female, 4-month-old C57BL/6 mice (20–25 g in weight;
The Jackson Laboratories, Bar Harbor, ME, USA) were
housed in covered cages, fed with a standard rodent diet
ad libitum, and kept on a 12 h light/12 h dark cycle. All
procedures concerning animals were performed in accor-
dance with the ARVO statement for the Use of Animals in
Ophthalmic and Vision Research and under protocols
approved by institutional IACUC committees at the Uni-
versity of California San Diego.
Induction of transient retinal ischemia
The mice were anesthetized with a mixture of ketamine
(100 mg/kg, Ketaset; Fort Dodge Animal Health, Fort
Dodge, IA, USA) and xylazine (9 mg/kg, TranquiVed;
Vedeco, Inc., St. Joseph, MO, USA) by intraperitoneal (IP)
injection. Eyes were also treated with 1 % proparacaine
drops. A 30-gauge needle was inserted into the anterior
chamber of right eye that was connected by flexible tubing
to a saline reservoir. By raising the reservoir, IOP was
elevated to 70–80 mmHg for 50 min. Sham treatment was
performed in the contralateral eyes by the insertion of a
needle in the anterior chamber without saline injection.
Retinal ischemia was confirmed by observing whitening of
the iris and loss of the retina red reflex. IOP was measured
with a tonometer (TonoLab; Tiolatoy, Helsinki, Finland)
during ischemia. Non-ischemic contralateral control retinas
were used as control.
Pharmacological treatment
CoQ10 was purchased from Kaneka Nutrients (Pasadena,
TX, USA) or Sigma (St. Louis, MO, USA). AIN-93G
purified control or a diet supplemented with CoQ10 were
formulated by Harlan Laboratories (Madison, WI, USA).
Four groups of mice were studied: a group of non-ischemic
C57BL/6 mice treated with control diet (n = 20 mice), a
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group of ischemic C57BL/6 mice treated with control diet
(n = 30 mice), a group of non-ischemic C57BL/6 mice
treated with 1 % CoQ10 diet [(v/v), which equals a daily
dose of 1,600–2,000 mg/kg body weight in 25–30 g mice,
n = 20 mice] [26] and a group of ischemic C57BL/6 mice
treated with 1 % CoQ10 diet (n = 30 mice).
Tissue preparation
Six to 24 h after acute IOP elevation, light adapted mice
were anesthetized with IP injection of mixture of ketamine/
xylazine, as described, and then mice were perfused tran-
scardially with 0.9 % saline followed by 4 % paraformal-
dehyde in 1X phosphate buffer saline (PBS, pH 7.4). Both
eyes enucleated and fixed in 4 % paraformaldehyde in PBS
for 4 h at 4 C. After several washes in PBS, the retinas
were dissected and then dehydrated through graded ethanol
solutions and embedded in polyester wax, as described
previously [27].
Whole-mount immunohistochemical analysis
Retinas from enucleated eyes were dissected as flattened
whole-mounts at 12 h or 2 weeks after ischemia–reperfu-
sion. Retinas were immersed in PBS containing 30 %
sucrose for 24 h at 4 C. The retinas were blocked in PBS
containing 3 % donkey serum, 1 % bovine serum albumin,
1 % fish gel and 0.1 % Triton X-100 for 1 h, and incubated
with goat polyclonal anti-Brn3a antibody (1:500; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), a specific
maker for RGCs [28, 29], and guinea pig polyclonal anti-
GFAP antibody (1:500; Advanced ImmunoChemical, Long
Beach, CA, USA) for 3 days at 4 C. After several wash
steps, the retinas were incubated with the secondary anti-
bodies, Alexa Fluor-568 donkey anti-goat IgG antibody or
Cy5-conjugated anti-guinea pig IgG antibody (Invitrogen,
Carlsbad, CA, USA) for 24 h, and subsequently washed
with PBS. The retinas were counterstained with the nucleic
acid stain Hoechst 33342 (1 lg/mL; Invitrogen) in PBS.
Images were captured under fluorescence microscopy
(Eclipse microscope, model E800; Nikon instruments Inc.,
Meliville, NY, USA) equipped with a digital camera
(SPOT; Diagnostic Instrument, Sterling Heights, MI,
USA). Images were acquired with commercial software
(Simple PCI version 6.0 software; Compix Inc., Cranberry
Township, PA, USA).
Quantitative analysis for RGC counting
To count RGCs labeled with Brn3a, each retinal quadrant
was divided into three zones by central, middle, and
peripheral retina [one sixth (*400 lm), three sixths
(*1,200 lm), and five sixths (*2,000 lm) of the retinal
radius from the optic nerve head]. Images were taken at
209, covering an area of 0.344 mm2, and then the number
of RGCs were normalized per mm2. RGC densities were
measured in 24 distinct areas (two areas at central, middle,
and peripheral per retinal quadrant) per condition by two
investigators in a masked fashion, and the scores were
averaged (n = 7 retinas/group). To further examine RGC
survival between control and CoQ10 diet-treated non-
ischemic retinas, RGC densities were automatically mea-
sured using ImageJ cell counting analysis (http://rsb.info.
nih.gov/ij/, National Institute of Health, Bethesda, MD,
USA).
Immunohistochemical analysis
Immunohistochemical staining of retinal cross sections at
12 h after transient ischemia was performed as previously
described [27]. Five sections per wax block from each
group were used for immunohistochemical analysis. Pri-
mary antibodies were goat polyclonal anti-Brn3a antibody
(1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
a specific maker for RGCs [30], monoclonal mouse anti-
GFAP antibody (1:500; Sigma, St. Louis, MO, USA) and
rabbit polyclonal anti-Iba1 antibody (1:500; Wako Chem-
icals USA, Inc., Richmond, VA, USA). To prevent non-
specific background, tissues were incubated in 1 % bovine
serum albumin/PBS for 1 h at room temperature before
incubation with the primary antibodies for 16 h at 4 C.
After several wash steps, the tissues were incubated with
the secondary antibodies, Alexa Fluor 568 dye-conjugated
donkey anti-goat IgG antibody (Invitrogen, Carlsbad, CA,
USA), Cy5 dye-conjugated goat anti-mouse IgG antibody
(Invitrogen) or Alexa Fluor 488 dye-conjugated anti-rabbit
IgG antibody (1:100; Invitrogen) for 4 h at 4 C and sub-
sequently washed with PBS. The sections were counter-
stained with the nucleic acid stain Hoechst 33342
(Invitrogen) in PBS. Images were acquired with confocal
microscopy (Olympus FluoView1000; Olympus, Tokyo,
Japan).
Western blot analysis
Following 6, 12 or 24 h after transient ischemia, the col-
lected retinas were homogenized in a glass-Teflon Potter
homogenizer in RIPA lysis buffer (150 mM NaCl, 1 mM
EDTA, 1 % NP-40, 0.1 % SDS, 1 mM DTT, 0.5 % sodium
deoxycholate and 50 mM Tris-Cl, pH 7.6) containing
complete protease inhibitors (Roche Biochemicals, India-
napolis, IN, USA). Each sample (10 lg; n = 3 retinas/
group) was separated by PAGE and electrotransferred to
polyvinylidenedifluoride membrane. The membrane was
blocked with 5 % nonfat dry milk and 0.1 % Tween-20 in
PBS for 1 h, incubated with rabbit polyclonal anti-SOD2
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antibody (1:5000; Santa Cruz Biotechnology), rabbit
polyclonal anti-HO-1 antibody (1:1000; Millipore),
monoclonal mouse anti-GFAP (1:3000; Sigma), rabbit
polyclonal anti-Iba-1 antibody (1:2000; Wako Chemical
USA), mouse monoclonal anti-caspase antibody (1:3000;
Cell Signaling, Danvers, MA, USA), rabbit polyclonal anti-
Bax antibody (1:500; Santa Cruz Biotechnology), mouse
monoclonal anti-phosphorylated Bad (pBad, 1:2000; Cell
Signaling), goat polyclonal anti-Tfam antibody (1:1000;
Santa Cruz Biotechnology), rabbit polyclonal anti-Porin
(1:1000; Calbiochem, La Jolla, CA, USA) and mouse
monoclonal anti-actin antibody (1:10,000, Millipore, Bill-
erics, MA, USA) for overnight at 4 C. After several
washes in Tween/PBS, the membranes were incubated with
peroxidase-conjugated donkey anti-goat IgG (1:5000: Bio-
Rad, Hercules, CA, USA), goat anti-rabbit IgG (1:5000;
Bio-Rad) or goat anti-mouse IgG (1:5000; Bio-Rad), and
developed using chemiluminescence detection (ECL Plus;
GE Healthcare Bio-Science, Piscataway, NJ, USA). The
scanned film Images were analysed by ImageJ (National
Institute of Health) and band densities were normalized to
the band densities for actin or porin.
TUNEL staining
The retinal cross sections at 12 h after transient ischemia
were incubated with proteinase K (10 lg/mL, 10 mM Tris,
pH 7.4–8.0) for 10 min at 37 C. After rinsing in PBS, the
sections were incubated with terminal deoxynucleotidyl
transferase plus nucleotide mixture in reaction buffer for
60 min at 37 C (In situ Cell Death Detection kit, Roche
Applied Science, Indianapolis, IN, USA) as previously
described [3]. To count TUNEL-positive cells, the areas
were divided into three layers by GCL, inner nuclear layer
(INL) and outer nuclear layer (ONL). TUNEL-positive
cells were counted in eight microscopic fields of 0.2 mm
from retinal sections per condition (n = 5 retinas/group) by
two investigators in a masked fashion, and the scores were
averaged.
Measurement of mtDNA content
MtDNA content of each sample at 12 h after transient
ischemia was determined as described previously [31].
Briefly, total genomic DNA (gDNA) was isolated from
retinas by using DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA, USA) as described in the manufacturer’s
protocol. For the measurement of relative mtDNA content,
real-time PCR was carried out using MX3000P real-time
PCR system (Stratagene, La Jolla, CA, USA) as following.
Total gDNAs (10 ng) from the each sample were amplified
using iQTM SYBR Green supermix (Bio-Rad, Hercules,
CA, USA) and mitochondrial cytocrome B (CytB-F:
50-GGTCTTTTCTTAGCCATACACTACA-30; CytB-R:
50-ATATCGGATTAGTCACCCGTAAT-30)orb-actin (ActB-
F; GATCGATGCCGGTGCTAAGA-30; ActB-R: 50-CAC
CATCACACCCTGTGGAAG-30) primers for 40 cycles
[initial incubation at 95 C for 10 min, and 40 cycles
(95 C for 30 s, 55 C for 30 s and 72 C for 20 s)].
Output data were obtained as Ct values and the difference
of mtDNA content among samples was calculated using
the comparative Ct method [32]. ActB gene was used to
normalize the ratio between mtDNA and gDNA. The
samples were run in triplicates for all experiment.
Statistical analysis
Data were presented as the mean ± SD. Comparison of
two or three experimental conditions was evaluated using
the unpaired, two-tailed Student’s t test or one-way ana-
lysis of variance and the Bonferroni t test. P \ 0.05 was
considered to be statistically significant.
Results
The effect of CoQ10 in IOP and body weight
We began either unsupplemented control or CoQ10 (1 %)-
supplemented diet treatment daily for 1 week before the
induction of transient retinal ischemia and then continued
diet treatment for 2 weeks (Fig. 1a). Transient retinal
ischemia was induced by acute IOP elevation to
71.8 ± 4.0 mmHg in mice treated with control diet
(n = 30 mice) and 70.3 ± 5.0 mmHg in mice treated with
CoQ10 diet (n = 30 mice) for 50 min (Fig. 1b). The pres-
sure was enough to induce retinal ischemia and the phe-
notype was similar to pathologic acute angle closure
glaucoma because when IOP reached 60 mmHg, the retina
flow rate decreased by 68 % for retinal artery in rodent
model [5, 33, 34]. The mean IOP of contralateral control
eyes was 8.4 ± 0.7 mmHg (n = 20 mice; Fig. 1b). In
addition, no difference was found in body weight between
control and CoQ10 diet-treated mice during experimental
period (n = 20 or 30 mice; Fig. 1b).
CoQ10 ameliorates oxidative stress in ischemic retina
We determined whether CoQ10 treatment prevents oxida-
tive stress-mediated upregulation of superoxide dismutase
2 (SOD2) and heme oxygenase-1 (HO-1) protein expres-
sion using antibodies raised against SOD2 and HO-1. We
observed that Increase of SOD2 protein expression was
maximal 12 h later by 1.36 ± 0.04-fold in ischemic retina
(P \ 0.05; Fig. 2a). The relative quantity of SOD2 pro-
tein expression was less at 24 h than at 12 h after
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ischemia–reperfusion. Intriguingly, CoQ10 treatment pre-
served SOD2 and HO-1 protein expression in ischemic
retina at 12 h compared with control diet-treated ischemic
retina (P \ 0.05; Fig. 2b), indicating that CoQ10 amelio-
rates oxidative stress in ischemic retinal injury.
CoQ10 promotes RGC survival in ischemic retina
Since CoQ10 is neuroprotective against retinal damage by
high IOP-induced transient ischemic injury and other
apoptotic insults [35, 36], we determined whether CoQ10
promotes RGC survival in ischemic retina using whole-
mount immunohistochemistry for Brn3a, a marker for
RGCs. Mean RGC density per retina for each group is
presented in Supplementary Table 1. Non-ischemic control
mouse retina had an average of 3329 ± 533 RGCs in the
central, 3326 ± 446 RGCs in the middle and 2230 ± 420
RGCs in the peripheral areas (n = 7 retinas) (Fig. 3a, b;
Supplementary Table 1). In comparison with non-ischemic
control retina treated with control diet, control diet treat-
ment showed about 32 % of RGC loss in ischemic retina
(P \ 0.01; Fig. 3a, b; Supplementary Table 1). In contrast,
CoQ10 significantly promoted RGC survival by an
approximate 21 % compared with control diet-treated
ischemic retina (P \ 0.05; Fig. 3a, b; Supplementary
Table 1). Astroglial and/or microglial activation coincide
with RGC degeneration in the hypertensive retina of
human, rat or mouse (3, 37–39). To investigate whether
CoQ10 blocks the activation of astroglial and microglial
cells in ischemic retina, we performed whole-mount
immunohistochemistry or Western blot analyses using
antibodies raised against glial fibrillary acidic protein
(GFAP), a marker for astroglial cells, or Iba1, a marker for
microglial cells. We found that GFAP and Iba1 immuno-
reactivity were increased in activated astroglia and mi-
croglial cells in the GCL and nerve fiber layer of control
diet-treated ischemic retina at 12 h, respectively (Fig. 4a).
Further, astroglial and microglial activation are accompa-
nied by RGC loss as indicated by significantly increased
GFAP and Iba-1 protein expression by 2.89 ± 0.49- and
11.8 ± 2.59-fold in control diet-treated ischemic retina at
Fig. 2 CoQ10-mediated blockade of oxidative stress in ischemic
injury. Unsupplemented control or CoQ10 (1 %) diet were daily
treated for 1 week before the induction of transient retinal ischemia
and continued for 6, 12 or 24 h. a SOD2 Western blot analyses at 6,
12 and 24 h after transient retinal ischemia. Increase of SOD2 protein
expression was maximal at 12 h in ischemic retina. The relative
expression level of SOD2 protein was less at 24 h than at 12 h after
ischemia–reperfusion. b SOD2 and HO-1 Western blot analyses at
12 h after transient retinal ischemia. CoQ10 treatment preserved
SOD2 and HO-1 protein expression in ischemic retina compared with
control diet-treated ischemic retina. Values are mean ± SD (n = 3
retinas/group). *Significant at P \ 0.05 compared with control-diet-
treated non-ischemic contralateral control retina or #Significant at
P \ 0.05 compared with control diet-treated ischemic retina. SOD2
superoxide dismutase 2, HO-1 hemeoxygenase-1
Fig. 1 CoQ10 supplementation and induction of transient retinal
ischemia. a Diagram for control and CoQ10 (1 %) supplementation
before and after ischemic injury. Unsupplemented control or CoQ10
diet were daily treated for 1 week before the induction of transient
retinal ischemia and continued for 2 weeks. b IOP elevation in the
mouse eyes and body weight in control diet- and CoQ10 diet-treated
mice following transient retinal ischemic injury
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12 h, respectively (P \ 0.05 for GFAP and P \ 0.01 for
Iba-1; Fig. 4b). In contrast, CoQ10 significantly decreased
GFAP and Iba-1 protein expression by 2.00 ± 0.23- and
1.38 ± 0.77-fold in ischemic retina at 12 h compared with
control diet-treated ischemic retina (P \ 0.05 for GFAP
and P \ 0.01 for Iba-1; Fig. 4b), indicating that CoQ10
prevents activation of astroglial and microglial cells in
ischemic retina by blocking oxidative stress. In addition,
there were no significant changes in RGC survival and
GFAP protein expression between control- and CoQ10-
treated control mice (Supplementary Fig. 1 and Supple-
mentary Table 2).
CoQ10 blocks apoptotic cell death by decreasing Bax
or by increasing pBad protein expression in ischemic
retina
To determine whether CoQ10 prevents apoptotic cell death
in ischemic retina, we performed TUNEL staining. There
were no TUNEL-positive cells in the retina of control mice
treated control diet (Fig. 5a, b). However, ischemic retinas
showed TUNEL-positive apoptotic cell death in the inner
nuclear layer (58 ± 10 per mm) and GCL (99 ± 18 per
mm) at 12 h (Fig. 5a, b). In contrast, there were no
TUNEL-positive cells in ischemic retina treated CoQ10 diet
(Fig. 5a, b). In comparison with control diet-treated non-
ischemic control retina, control diet-treated ischemic retina
showed a significant induction of cleaved caspase-3 protein
expression at 12 h by 2.68 ± 0.29-fold (P \ 0.01;
Fig. 5c). However, CoQ10 significantly reduced cleaved
caspase-3 protein expression at 12 h by 0.98 ± 0.21-fold
in ischemic retina (P \ 0.01; Fig. 5c).
Our previous study showed that ischemic injury induces
a significant increase of Bax and pBad protein expression
in the early apoptotic pathway-mediated neurodegeneration
of rat retina [5]. To determine whether CoQ10 modulates
apoptotic cell death pathway in ischemic retina, we per-
formed Western blot analysis using antibodies for Bax and
pBad. We found that Bax protein expression was signifi-
cantly increased by 2.71 ± 0.25-fold in ischemic retina at
12 h compared with control diet-treated non-ischemic
control retina (P \ 0.01; Fig. 6). In contrast, CoQ10 sig-
nificantly decreased Bax protein expression by
1.61 ± 0.15-fold in ischemic retina at 12 h compared with
control diet-treated ischemic retina (P \ 0.01; Fig. 6).
pBad protein expression was significantly increased by
8.02 ± 0.56-fold in ischemic retina at 12 h compared with
control diet-treated non-ischemic control retina (P \ 0.01;
Fig. 6). Intriguingly, CoQ10 showed greater increase of
pBad protein expression by 9.31 ± 0.39-fold in ischemic
retina at 12 h compared with control diet-treated ischemic
retina (P \ 0.05; Fig. 6), suggesting that CoQ10 protects
RGCs against oxidative stress-mediated apoptotic cell
death by decreasing Bax or by increasing pBad protein
expression in ischemic retina.
CoQ10 preserves Tfam protein expression in ischemic
retina
To determine whether oxidative stress induced by acute
IOP elevation alters mtDNA content and whether CoQ10
preserves this alteration in ischemic retina, mtDNA content
was determined by real-time PCR analysis. We found that
there were no differences in mtDNA content among control
diet-treated non-ischemic control, and control diet-treated
ischemic and CoQ10-treated ischemic retinas at 12 h
(Fig. 7a). Oxidative stress triggers increase of Tfam protein
expression in ischemic rat retina [5]. To determine whether
CoQ10 preserves this alteration in ischemic retina, we
examined the expression level of Tfam using Western blot
analysis. We observed that Increase of Tfam protein
expression was maximal 12 h later by 1.86 ± 0.12-fold in
ischemic retina (P \ 0.05; Fig. 7b). The relative expres-
sion level of Tfam protein was less at 24 h than at 12 h in
ischemic retina. Intriguingly, CoQ10 treatment partially
preserved Tfam protein expression at 12 h compared with
control diet-treated ischemic retina (P \ 0.05; Fig. 7c).
Fig. 3 CoQ10-mediated protection of RGC survival in ischemic
retina. Unsupplemented control or CoQ10 (1 %) diet were daily
treated for 1 week before the induction of transient retinal ischemia
and continued for 2 weeks. a Brn3a whole-mount immunohistochem-
istry at 2 weeks after transient retinal ischemia. High magnification
showed representative images from the middle area of retinas.
b Quantitative analysis of RGC survival. Values are mean ± SD
(n = 7 retinas/group). §Significant at P \ 0.05 and **Significant at
P \ 0.01 compared with control diet-treated non-ischemic control
retina or #Significant at P \ 0.05 compared with control diet-treated
ischemic retina. Scale bar 50 lm
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Fig. 4 CoQ10-mediated




CoQ10 (1 %) diet were daily
treated for 1 week before the
induction of transient retinal
ischemia and continued for
12 h. a Double
immunohistochemistry for
GFAP and Iba-1 at 12 h after
transient retinal ischemia.
Control diet-treated Ischemic
retina increased GFAP and Iba-
1 immunoreactivites in the GCL
compared with control diet-
treated non-ischemic control
retina. In contrast, CoQ10
treatment decreased GFAP and
Iba1 immunoreactivities in the
GCL of ischemic retina.
Intriguingly, higher
magnification showed a
quiescent microglial cell that
has ramified long and thin
processes in control diet-treated




retina showed an activated
microglial cell that has
thickened processes
(arrowheads) and swollen cell
body (arrow). GCL ganglion
cell layer. Scale bars 50 lm.
b GFAP and Iba-1 Western blot
analyses at 12 h after transient
retinal ischemia. Control diet-
treated ischemic retina
significantly increased GFAP
and Iba-1 protein expression




decreased GFAP and Iba-1
protein expression in ischemic
retina. Values are mean ± SD
(n = 3 retinas/group).
*,§Significant at P \ 0.05 and
**Significant at P \ 0.01
compared with control diet-
treated non-ischemic control
retina or #Significant at
P \ 0.05 and ##Significant at
P \ 0.01 compared with control
diet-treated ischemic retina
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However, there was no difference in expression level of
porin protein between control diet- and CoQ10 diet-treated
ischemic retina. These results suggest that oxidative stress
induced by acute IOP elevation increases Tfam protein
expression but shows no alteration of mtDNA content in
ischemic retina.
Discussion
CoQ10 is an attractive neurotherapeutic agent for retinal
protection against high IOP elevation-induced oxidative
stress in retinal ischemic injury [24, 25] as well as other
neurodegenerative diseases including Parkinson’ and
Huntington’s diseases [20, 26, 40–42]. Moreover, CoQ10 is
neuroprotective in retinal cells in vivo and in vitro against
oxidative stress and excitotoxicity [23, 35, 41]. It has been
reported that that CoQ10 supplements correlated with
plasma CoQ10 level and CoQ10 in large doses was taken up
all tissues including heart and brain mitochondria [43],
suggesting that CoQ10 could also be taken up by retina and
lead to a beneficial effect in ischemic retina injury. In
support of this notion, a recent study demonstrated that oral
supplementation of CoQ10 was neuroprotective against
retinal damage induced by intravitreal injection of
N-methyl-d-aspartate in mice in vivo [23]. In the current
study, we addressed the question of whether a CoQ10-
supplemented diet inhibits oxidative stress-mediated
Fig. 5 CoQ10-mediated blockade of apoptotic cell death in ischemic
retina. Unsupplemented control or CoQ10 (1 %) diet daily were daily
treated for 1 week before the induction of transient retinal ischemia
and continued for 12 h. a TUNEL staining at 12 h after transient
retinal ischemia. There were no TUNEL-positive cells in the GCL
and INL of control diet-treated non-ischemic retina. However, control
diet-treated ischemic retina showed TUNEL-positive apoptotic cell
death in the GCL and INL at 12 h (arrows). In contrast, there were no
TUNEL-positive cells in CoQ10 diet-treated ischemic retina. INL
inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell
layer, nd non-detectable, ONL outer nuclear layer, OPL outer
plexiform layer. Scale bar 20 lm. b Quantitative analysis of
TUNEL-positive cells at 12 h after transient retinal ischemia. Values
are mean ± SD (n = 5 retinas/group). c Caspase-3 Western blot
analysis at 12 h after transient retinal ischemia. Control diet-treated
ischemic retina significantly increased induction of cleaved caspase-3
protein expression compared with control diet-treated non-ischemic
control retina. In contrast, CoQ10 treatment significantly decreased
cleaved caspase-3 protein expression in ischemic retina compared
with control diet-treated ischemic retina. Values are mean ± SD
(n = 3 retinas/group). **Significant at P \ 0.01 compared with
control diet-treated non-ischemic control retina or ##Significant at
P \ 0.01 compared with control diet-treated ischemic retina
Fig. 6 CoQ10-mediated blockade of apoptotic pathway in ischemic
retina. Unsupplemented control or CoQ10 (1 %) diet were daily
treated for 1 week before the induction of transient retinal ischemia
and continued for 12 h. Bax and pBad Western blot analyses at 12 h
after transient retinal ischemia. Control diet-treated ischemic retina
significantly increased Bax and pBad protein expression. In contrast,
CoQ10 treatment significantly decreased Bax protein expression, but
increased pBad protein expression in ischemic retina compared with
control diet-treated ischemic retina. Values are mean ± SD (n = 3
retinas/group). §Significant at P \ 0.05 and **,§§Significant at
P \ 0.01 compared with control diet-treated non-ischemic control
retina or #Significant at P \ 0.05 and ##Significant at P \ 0.01
compared with control diet-treated ischemic retina. pBad phosphor-
ylated Bad
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mitochondrial dysfunction and RGC degeneration in
ischemic retina.
We previously reported that acute IOP elevation triggers
the upregulation of SOD2 protein expression and this
increase could be restored by brimonidine (BMD)-mediated
blockade of glutamate excitotoxicity-induced oxidative
stress in ischemic rat retina [5]. Consistent with these
results, we have now found that the upregulation of SOD2
and HO-1 protein expression by acute IOP elevation was
maximal early the neurodegeneration (12 h) of retinal
ischemia. However, CoQ10 treatment decreases SOD2 and
HO-1 protein expression in ischemic retina. Endogenous
antioxidants such as mitochondrial SOD2 that localizes in
the mitochondrial matrix and catalyzes the dismutation of
superoxide radicals normally regulate ROS generated in
mitochondria [44, 45]. It has been reported that SOD2
expression is increased by the stimulation of mitochondrial
superoxide anion (O2
-) [46] and CoQ10 treatment could
reduce the O2
- production [47]. Growing evidence indicates
that overexpression of the SOD2 gene inhibits retinal dam-
age by reducing oxidative stress and nitrosative stress [48],
as well as protecting retinal vascular cells and capillary
degeneration against apoptotic cell death in mouse models
of ischemic injury [49]. Moreover, the upregulation of
SOD2 is accompanied by a higher resistance to oxidative
stress as well as SOD2 activity directly stabilizing mito-
chondrial transmembrane potential and calcium buffering
ability [50, 51]. Our results, therefore, raise the possibility
that increasing SOD2 or HO-1 expression in retinal ische-
mic injury may contribute to compensatory endogenous
antioxidant mechanisms that increase resistance or stabil-
ization of mitochondria against acute IOP elevation-induced
oxidative stress. Taken together, it is noteworthy that these
results suggest that CoQ10 could be an important antioxidant
for ameliorating oxidative stress-mediated neurodegenera-
tion in ischemic retina. Studying the benefits of CoQ10-
mediated blockade of oxidative stress or enhancement of
antioxidant enzymes may be a novel strategy for protecting
retinal neurons against ischemic injury.
In the current study, we observed that CoQ10 treatment
significantly promoted RGC survival as well as blocked acti-
vation of astroglial and microglial cells in ischemic retina.
Astroglial or microglial activation coincides with RGC
degeneration in the hypertensive retina of human, rat or mouse
[3, 5, 37–39]. Thus, it is possible that CoQ10-mediated blockade
of oxidative stress may indirectly reduce astroglial or microglial
activation in the retina against elevated IOP-induced ischemic
damage as a result of increased RGC survival. Regardless, it
cannot be excluded that CoQ10 may prevent glial activation by
blocking oxidative stress in astroglial or microglial cells in
ischemic retina. CoQ10 is also neuroprotective in retinal glial
cells against oxidative stress, since oxidative stress has
remarkably linked to glial cell activation or reaction in the retina
or optic nerve still needs to be ascertained [5, 52–56]. In addi-
tion, interestingly, it has been reported that IOP induced the
upregulation of GFAP and major histochompatibility complex
class II molecule, as well as of microglial activity in the con-
trolateral control retinas in experimental rodent models of
glaucoma induced by laser treatment [57, 58]. Although there
was no evidence of glial activation in the contralateral non-
ischemic control retina in the current study, future studies will
need to clarify to use contralateral retina as an internal control in
our ischemic model of mice.
Consistent with our result that CoQ10 promoted RGC
survival in ischemic retina, we found that CoQ10 significantly
decreased Bax, but increased pBad protein expression in
ischemic retina. Bax is a pro-apoptotic member of the Bcl-2
Fig. 7 CoQ10-mediated restoration of Tfam protein expression in
ischemic retina. Unsupplemented control or CoQ10 (1 %) diet were
daily treated for 1 week before the induction of transient retinal
ischemia and continued for 12 h. a mtDNA content at 12 h after
transient retinal ischemia. Real-time PCR analysis showed that there
were no differences in mtDNA content among groups. (b, and c)
Tfam Western blot analysis at 12 h after transient retinal ischemia.
b Tfam Western blot analyses at 6, 12 and 24 h after transient retinal
ischemia. Increase of Tfam protein expression was maximal at 12 h in
control diet-treated ischemic retina. The relative concentration of
Tfam protein expression was less at 24 h than at 12 h after ischemia–
reperfusion. c Tfam Western blot analysis at 12 h after transient
retinal ischemia. CoQ10 treatment preserved Tfam protein expression
at 12 h in ischemic retina compared with control diet-treated ischemic
retina. Values are mean ± SD (n = 3 retinas/group). *,§Significant at
P \ 0.05 compared with control diet-treated non-ischemic control
retina or #Significant at P \ 0.05 compared with control diet-treated
ischemic retina. Tfam mitochondrial transcription factor A, mtDNA
mitochondrial DNA
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family that is essential in many apoptotic pathways [59, 60] as
well as directly interacts with the component forming the
mitochondrial permeability transition pore (MPTP) that
allows proteins to escape from the mitochondria into the
cytosol to initiate apoptosis [61–63]. Bax is counteracted by
Bcl-xL that forms heterodimers with dephosphorylation of
Bad, which inactivates Bcl-xL; and pBad eliminates this
dimerization, which activates Bcl-xL [64, 65]. Our collective
results suggest that CoQ10 promotes RGC survival against the
mitochondria-related apoptotic pathway in ischemic retinal
injury by decreasing Bax, but by increasing pBad protein
expression. These results reflect the possibility that increased
pBad expression may represent an endogenous repair mech-
anism against apoptotic pathway and that CoQ10 may con-
tribute to the blockade of Bax-mediated increase of MPT or
the promotion of mitochondrial homeostasis in ischemic
injury. The MPTP opening leads to loss of mitochondrial
membrane potential, mitochondrial swelling, rupture of the
outer mitochondrial membrane and release of cytochrome c.
Importantly, MPTP opening by calcium overload and oxi-
dative stress leads to necrosis rather than apoptosis [66, 67].
Recently, MPTP-mediated neuronal cell death has been
implicated as an important pathophysiological mechanism
for mitochondrial dysfunction in ischemic injury [24, 25].
Taken together, out findings suggest that CoQ10 may promote
RGC survival by inhibiting not only apoptosis but also
necrosis in ischemic retinal injury.
Ischemic injury triggers mitochondrial dysfunction
including ROS induction as well as mtDNA damage, Tfam
alteration or OXPHOS impairment in the central nervous
system [5, 19, 68]. Recently, we have reported that acute
IOP elevation significantly increased Tfam/OXPHOS
complex protein expression and that blockade of glutamate
excitotoxicity-induced oxidative stress by BMD treatment
preserved Tfam/OXPHOS complex protein expression in
ischemic retina [5], suggesting that the preservation of
Tfam/OXPHOS complex may provide therapeutic potential
for protecting RGCs against mitochondrial dysfunction
induced by glutamate excitotoxicity and/or oxidative stress
in ischemic retina [5]. In the current study, we observed
that retinal ischemic injury triggers significant increase of
Tfam protein expression in the early neurodegenerative
events (6–12 h) and CoQ10 decreases Tfam protein
expression in ischemic retina at 12 h. Emerging evidence
suggests that the Tfam and OXPHOS complex IV are
rapidly increased in the early neurodegenerative events of
neonatal hypoxic-ischemic brain injury, suggesting that
Tfam may contribute to endogenous repair mechanism of
injured brain neurons [19]. Further, recent studies reported
that overexpression of Tfam protects mitochondria against
b–amyloid-induced oxidative damage in human SH-SY5Y
neuroblastoma cells and ameliorates delayed neuronal cell
death in the hippocampus following transient forebrain
ischemia in mice [16, 17]. In contrast, in mice lacking Tfam
there is impaired mtDNA transcription and mtDNA loss is
triggered; this leads to mitochondrial bioenergetic dys-
function-mediated embryonic lethality [12].
Based on these results, we suggest that CoQ10-mediated
preservation of Tfam expression may provide a potential
mechanism for protecting RGCs against oxidative stress-
induced mitochondrial dysfunction in ischemic retina.
Future studies will examine the precise molecular mecha-
nism underlying CoQ10-mediated Tfam preservation in
ischemic retina. Although mtDNA is particularly suscepti-
ble to oxidative stress [69], it is unknown whether oxidative
stress can directly trigger mtDNA alteration in ischemic
retina. Interestingly, we found that there was no statistical
difference in mtDNA content among control diet- and
CoQ10 diet-treated groups. Because it has been reported that
Tfam regulates mtDNA copy numbers in mammals and the
levels of Tfam correlate with the levels of mtDNA [15, 70],
our findings that did not show a correlation between Tfam
protein expression and mtDNA content raise the possibility
that increasing Tfam protein expression may prevent alter-
ation of mtDNA content against oxidative stress in ischemic
retina. Regardless, it would be useful to investigate mtDNA
alteration on ischemic retina using measurements for
8-hydroxy-2-deoxyguanosine and mitochondrial membrane
potential, and future studies need to address this more detail.
In conclusion, these results provide direct evidence that
CoQ10 promotes RGC survival in ischemic mouse retina by
inhibiting oxidative stress and by blocking the Bax/Bad-
mediated mitochondrial apoptotic pathway. Moreover,
CoQ10 also preserves Tfam protein expression in ischemic
mouse retina. Based on these observations, we suggest that
CoQ10 may provide a promising therapeutic potential for
ameliorating oxidative stress-mediated mitochondrial dys-
function in ischemic retinal injury.
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